GSDMD

Across TCGA pan-cancer cohorts, GSDMD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSDMD data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GSDMD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GSDMD expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where GSDMD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.839	0.206	<.001	25	view →
CCRCC	OS	Median	III,IV	0.985	0.237	.017	10	view →
PDAC	DFS	Quartile	III,IV	0.401	0.984	.010	9	view →
HNSC	DFS	Tertile	All	0.907	0.991	.024	5	view →
GBM	DFS	Median	All	0.648	0.843	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GSDMD–LUAD (OS)

Open the LUAD breakdown →